Stifel Nicolaus Sticks to Their Hold Rating for Denali Therapeutics (DNLI)
Optimistic Outlook for Denali Therapeutics: Buy Rating Affirmed Amidst Positive ERT Developments and Strong Pipeline Progress
Stifel Adjusts Price Target on Denali Therapeutics to $22 From $26, Maintains Hold Rating
Wedbush Maintains Outperform on Denali Therapeutics, Lowers Price Target to $30
Wedbush:维持Denali Therapeutics(DNLI.US)评级,由优于大市调整至优于大市评级, 目标价由31.00美元调整至30.00美元。
Denali Therapeutics Analyst Ratings
Stifel Maintains Hold on Denali Therapeutics, Lowers Price Target to $22
Wedbush Adjusts Denali Therapeutics' Price Target to $30 From $31, Keeps Outperform Rating
HC Wainwright & Co. Reiterates Buy on Denali Therapeutics, Maintains $95 Price Target
Analysts Offer Insights on Healthcare Companies: Valneva (VALN), Denali Therapeutics (DNLI) and Armata Pharmaceuticals (ARMP)
UBS: Maintains Denali Therapeutics (DNLI.US) rating, adjusted from buy to buy rating, and adjusted target price from $70.00 to $32.00.
Denali Therapeutics Analyst Ratings
UBS Adjusts Denali Therapeutics Price Target to $32 From $70, Maintains Buy Rating
Analysts Offer Insights on Healthcare Companies: Straumann Holding AG (Six Swiss: CH:STMN), Denali Therapeutics (DNLI) and ArGEN X (GB:0QW0)
Denali Therapeutics (DNLI) Gets a Buy From Oppenheimer
Strong Growth and Value Potential Justify Buy Rating for Denali Therapeutics Despite Dilution
Goldman Sachs Maintains Buy on Denali Therapeutics, Lowers Price Target to $50
B. Riley Securities Adjusts Denali Therapeutics' Price Target to $36 From $38, Keeps Buy Rating
Wedbush Reiterates Outperform on Denali Therapeutics, Maintains $31 Price Target
Denali Therapeutics Analyst Ratings
No Data